-PTI GANDHINAGAR: The Comptroller and Auditor General of India (CAG) has come down heavily on the Gujarat government and state Public Sector Undertakings for causing a loss of nearly Rs 580 crore to the exchequer by bestowing "undue" favours to large corporate entities. The major industrial houses to whom the Narendra Modi government played the benefactor included Reliance Industries Ltd (RIL), Essar Steel and Adani Power Ltd (APL), the report for year...

-The Times of India LUCKNOW: As a weaver at a small zardozi unit in Sheesh Mahal area, Aftab Husain barely managed to make Rs 100 per day. Already struggling to make ends meet, Husain got the shock of his life when doctors at King George Medical College, Lucknow, found that his newborn daughter was suffering from total anomalous pulmonary venous connection (TAPVC), a rare congenital heart ailment often referred to as...

-The Times of India KOLKATA: A 22-year-old post graduate student and leader of CPM's students' wing SFI, died of injuries sustained in police custody, prompting the Left Front to demand a judicial probe on Tuesday while chief minister Mamata Banerjee and her senior cabinet colleagues attended the IPL inauguration ceremony barely a few km away. Police claimed SFI state committee member Sudipto Gupta's death was an accident while the victim's kin alleged...

-The Business Standard Interview with Founder chairman of Cancer Patients Aid Association Though the legal battle over Glivec's patentability may be over for now, Y K Sapru, the man spearheading the fight against Swiss multinational Novartis, isn't resting. Sapru, founder chairman of Cancer Patients Aid Association, or CPAA (which moved the Supreme Court to keep the prices of the cancer drug low), tells Sushmi Dey what the judgment means to cancer patients....

-The Economic Times WASHINGTON: Big Pharma found little support from the small guy on the street as the Indian Supreme Court's decision to reject patent claims of the drug maker Novartis for its celebrated cancer medicine Glivec reverberated across the world. The pharma lobby railed against the decision but the overwhelming sentiment, from physicians to politicians, from academia to media, particularly in a country groaning from the high cost of health care,...